{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:23Z","timestamp":1792431983299,"version":"4.5.0"},"reference-count":10,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To evaluate the impact of the elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) combination on the small airways in adults with cystic fibrosis (CF), a genetic disorder that primarily affects the respiratory system, leading to progressive lung disease. In CF, the small airways play a critical role, contributing to chronic symptoms such as cough, sputum production, and dyspnea. Methods: This was a single-center, retrospective observational study of adults with CF treated with ELX\/TEZ\/IVA for 12 months. We compared the patients who were homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene with those who were heterozygous for that mutation, in terms of lung function outcomes (FEV1, FEF25-75%, and the RV\/TLC ratio) and the extent of non-homogeneous ground-glass opacity. Among the patients within the cohort, the same parameters were evaluated separately in those who had advanced lung disease and in those who had previously undergone CFTR modulator therapy. Results: There was a significant post-treatment improvement in lung function, with a median increase of 0.42 L\/s in the FEF25-75% (p &lt; 0.001) and a 5% reduction in the mean RV\/TLC ratio (p &lt; 0.001). There was a trend toward a higher improvement the F508del homozygous patients. A significant reduction in non-homogeneous ground-glass opacity was observed in 79.5% of the patients. Among the patients with advanced lung disease, there were notable post-treatment improvements in all of the parameters assessed. Conclusions: Our results highlight the positive impact that ELX\/TEZ\/IVA treatment can have on small airway function in patients with CF, with potential benefits even for those with advanced lung disease. Further research is needed in order to evaluate the long-term effects of this treatment and its relationship with patient-reported outcomes.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240406","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:09:14Z","timestamp":1743624554000},"page":"e20240406","source":"Crossref","is-referenced-by-count":1,"title":["Impact of elexacaftor\/tezacaftor\/ivacaftor on the small airways in cystic fibrosis"],"prefix":"10.36416","author":[{"given":"Sofia","family":"Campos Silva1","sequence":"first","affiliation":[{"name":"1. Hospital Beatriz \u00c2ngelo, ULS Loures-Odivelas, Loures, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Barroso2","sequence":"additional","affiliation":[{"name":"2. Hospital de Faro, ULS do Algarve, Faro, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cunha3","sequence":"additional","affiliation":[{"name":"3. Hospital de Vila Franca de Xira, ULS Estu\u00e1rio do Tejo, Vila Franca de Xira, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Fragoso4,5","sequence":"additional","affiliation":[{"name":"4. Hospital de Santa Maria, ULS de Santa Maria, Lisboa, Portugal. 5. Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Azevedo4,5","sequence":"additional","affiliation":[{"name":"4. Hospital de Santa Maria, ULS de Santa Maria, Lisboa, Portugal. 5. Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Guo J, Garratt A, Hill A, Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456-462. https:\/\/doi.org\/10.1016\/j.jcf.2022.01.009","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Elborn JS. Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"ref2","unstructured":"3.           Davis S D, Brody AS, Ratjen F. Cystic Fibrosis. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, editors. Fishman\u2019s Pulmonary Diseases and Disorders. 6th ed. New York: McGraw Hill; 2022. p. 815-835"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Rep\u00fablica Portuguesa. Servi\u00e7o Nacional de Sa\u00fade, Autoridade Nacional do Medicamento e Produtos de Sa\u00fade (Infarmed) [homepage on the Internet] Lisboa: Infarmed; c2020 [updated 2022 Feb 21; cited 2024 Nov 08]. Relat\u00f3rio de avalia\u00e7\u00e3o de financiamento p\u00fablico de Medicamento Kaftrio (elexacaftor-tezacaftor-ivacaftor) + Kalydeco (ivacaftor). [Adobe Acrobat document, 25p.]. Available from: https:\/\/tinyurl.com\/58s4nadu","DOI":"10.29327\/congresso-nacional-de-pesquisas-em-saude-376034.749550"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Keogh RH, Cosgriff R, Stephenson A, et al. Real-world longitudinal outcomes of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis. Respir Med. 2024;107882. https:\/\/doi.org\/10.1016\/j.rmed.2024.107882","DOI":"10.1101\/2024.03.15.24304343"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948. https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1016\/s0140-6736(19)32597-8"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1056\/nejmoa1908639"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32:100690. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100690","DOI":"10.1016\/s1569-1993(23)01220-1"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Nichols DP, Paynter AC, Heltshe SL, Donaldson H, Frederick CA, Freedman SD, et al., Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial, Am. J. Respir. Crit. Care Med. 205(5):529-539. https:\/\/doi.org\/10.1164\/rccm.202108-1986OC","DOI":"10.1164\/rccm.202108-1986oc"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.        Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, et al., Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Inter-im Results of an Open-Label Phase 3 Clinical Trial, Am J Respir Crit Care Med. 203(3):381-385. https:\/\/doi.org\/10.1164\/rccm.202008-3176LE","DOI":"10.1164\/rccm.202008-3176le"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:09:18Z","timestamp":1743624558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4086\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":10,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240406","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}